Defunct Company
Total Trials
21
As Lead Sponsor
20
As Collaborator
1
Total Enrollment
4,718
NCT00617695
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Phase: Phase 3
Role: Lead Sponsor
Start: Sep 30, 2003
Completion: Oct 31, 2004
NCT00239564
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
Phase: Phase 1/2
Start: Oct 31, 2005
Completion: Dec 31, 2007
NCT00253084
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
Phase: Phase 2
Start: Nov 30, 2005
NCT00279825
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
Start: Jan 31, 2006
NCT00488839
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
Start: Jun 30, 2007
Completion: May 31, 2008
NCT00869791
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
Start: Nov 30, 2008
Completion: Jun 30, 2009
NCT00880620
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
Start: Apr 30, 2009
Completion: Nov 30, 2010
NCT00914290
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
Completion: Feb 28, 2010
NCT00974974
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
Start: Sep 30, 2009
Completion: Mar 31, 2011
NCT01096186
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
Start: Mar 31, 2010
Completion: Oct 31, 2011
NCT01130493
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
Start: May 31, 2010
Completion: Jan 31, 2012
NCT01411137
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
Start: Aug 31, 2011
Completion: Mar 31, 2013
NCT01521663
Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)
Start: Nov 30, 2011
Completion: Feb 28, 2013
NCT02271503
A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease
Start: Nov 30, 2015
Completion: Aug 31, 2016
NCT02770365
Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy
Role: Collaborator
Start: May 31, 2016
Completion: Nov 30, 2016
NCT03007888
A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Start: Nov 14, 2016
Completion: Aug 1, 2017
NCT03275922
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
Start: Nov 27, 2017
Completion: Sep 28, 2020
NCT03670953
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
Start: Nov 6, 2018
Completion: Jun 15, 2021
NCT03877510
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
Start: Apr 3, 2019
Completion: Mar 21, 2022
NCT06161220
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
Phase: Phase 1
Start: Oct 30, 2023
Completion: Dec 5, 2023
NCT06765668
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Phase: Phase 4
Start: Feb 12, 2025
Completion: Aug 6, 2026